Skip to main content

REVIEW article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1405727
This article is part of the Research Topic Regulation of Immune Subsets in Tumor Microenvironment View all articles

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Provisionally accepted
Yang Yu Yang Yu 1Mengdie Yu Mengdie Yu 2Lijie luo Lijie luo 3zijing zhang zijing zhang 3Haiping zeng Haiping zeng 3yan chen yan chen 3Zeyu lin Zeyu lin 3mengnan chen mengnan chen 4Wei Wang Wei Wang 3*
  • 1 The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
  • 2 Guangzhou Kingmed Diagnostics Group Co., Ltd., Guangzhou, China
  • 3 Department of Endocrinology, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong Province, China
  • 4 Department of Thyroid and Breast Surgery, Baiyun Hospital, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China

The final, formatted version of the article will be published soon.

    Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours, arising mainly from the interstitial cells of Cajal (ICCs) of the gastrointestinal tract. As radiotherapy and chemotherapy are generally ineffective for GISTs, the current primary treatment is surgical resection. However, surgical resection is not choice for most patients. Therefore, new therapeutic strategies are urgently needed. Targeted therapy, represented by tyrosine kinase inhibitors (TKIs), and immunotherapy, represented by immune checkpoint inhibitor therapies and chimeric antigen receptor T-cell immunotherapy (CAR-T), offer new therapeutic options in GISTs and have shown promising treatment responses. In this review, we summarize the molecular classification and immune microenvironment of GISTs and discuss the corresponding targeted therapy and immunotherapy options. This updated knowledge may provide more options for future therapeutic strategies and applications in GISTs.

    Keywords: Gastrointestinal Stromal Tumours, Immunotherapy, targeted therapy, Molecular Characteristics, immune microenvironment

    Received: 23 Mar 2024; Accepted: 24 Jun 2024.

    Copyright: © 2024 Yu, Yu, luo, zhang, zeng, chen, lin, chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wei Wang, Department of Endocrinology, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.